You have at least 8-10 million people with Hepatitis C in India; you are leaving behind 10-15% difficult-to-treat patients, and you have new infections of this silent killer every year. Yet you can eradicate it, like Polio. Because there’s a drug. So, what’s next?
Gilead’s voluntary license to Indian generic makers for sofosbuvir three years ago, brought down the price from $1000 a pill to $10, and then to $3 a pill. Leading doctors believe it’d hit $1/pill soon
Many manufacturers have decamped. The remaining ones believe just reducing the price will not wipe out this virus which can remain dormant for as long as 20 years, eating away the liver
Doctors are advocating a ‘recall policy’ on one hand and a national programme on the other. Both require resources for diagnostics and drugs. A PIL towards this is now accepted in the Delhi High Court
By the time Gilead’s voluntary license comes up for renewal in two years, would drug companies, government and Indians be moving towards Hep C eradication?
Every once in a while comes a discovery that brings about a seismic change. And every once in a while, also comes a business decision that enhances the seismic effect. One such discovery was the drug sofosbuvir, approved in late 2013 by the US regulator for treating Hepatitis C.
By registering, you will be signed-up for an account which gives you access to a free story published once a week and archives of all our free stories. You will also receive a daily newsletter sent to your inbox. To unsubscribe, please visit the profile section in your account.
What you get
Access all free stories
239+ archived free stories, and all upcoming ones too.
Paid story summaries
Read an exclusive 200 word summary for all our paid stories.
Our world-renowned emails, in your inbox, every day.
The Ken is a subscription-driven media site. We write one story a day (weekdays only). These stories have sharp, original insights on technology, business, science and healthcare from India.
Why do I have to sign up to read your stories?
Our stories are not free. Well, some select stories are. But, a significant part of what we write at The Ken is for subscribers only. We put in a lot of effort and resources in writing our stories and believe that you must pay for good journalism. Hence, our three plans.
1) The annual membership
2) The free sign up
3) The recurring quarterly subscription
On journalism and why you should pay for it, if you haven’t already seen it, here’s a great explainer from John Oliver.
So, one must pay for journalism?
How many stories will I get if I take an annual membership?
And, in the free sign up?
Four stories every month.
Do I get a refund?
We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.
I am not getting my daily emails. Do I have to whitelist emails from The Ken?
An added benefit of your subscription (free/paid) are the daily personalised emails. These emails, at times, might end up in your spam/junk folder due to emojis, attachments or images. In case you’re not receiving these emails, it might help to whitelist us. If the problem still persists, write to us at [email protected].
Why am I unable to access the archives?
Full and unrestricted access to our archives is a feature of our annual membership.
Dear subscriber - a lot of hard work goes into the journalism we put out. While sharing snippets or limited screenshots is okay, please avoid printing and sharing our entire articles as PDFs. Our plans are very affordable - please ask your friends to subscribe.
"An article from The Ken has become an intrinsic part of my daily news diet."
Nandan Nilekani, Former Chairman, UIDAI
Welcome to The Ken
As a part of the Learning and Development program at Myntra-Jabong, you have complete access to 300+ original daily stories over the next year, 500+ previously published stories and our comment sections. Also, do keep an eye out for our exclusive subscriber-only iOS and Android apps which will be rolled out for you shortly.